» Articles » PMID: 24101511

MiRNA and MRNA Cancer Signatures Determined by Analysis of Expression Levels in Large Cohorts of Patients

Overview
Specialty Science
Date 2013 Oct 9
PMID 24101511
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Toward identifying a cancer-specific gene signature we applied surprisal analysis to the RNAs expression behavior for a large cohort of breast, lung, ovarian, and prostate carcinoma patients. We characterize the cancer phenotypic state as a shared response of a set of mRNA or microRNAs (miRNAs) in cancer patients versus noncancer controls. The resulting signature is robust with respect to individual patient variability and distinguishes with high fidelity between cancer and noncancer patients. The mRNAs and miRNAs that are implicated in the signature are correlated and are known to contribute to the regulation of cancer-signaling pathways. The miRNA and mRNA networks are common to the noncancer and cancer patients, but the disease modulates the strength of the connectivities. Furthermore, we experimentally assessed the cancer-specific signatures as possible therapeutic targets. Specifically we restructured a single dominant connectivity in the cancer-specific gene network in vitro. We find a deflection from the cancer phenotype, significantly reducing cancer cell proliferation and altering cancer cellular physiology. Our approach is grounded in thermodynamics augmented by information theory. The thermodynamic reasoning is demonstrated to ensure that the derived signature is bias-free and shows that the most significant redistribution of free energy occurs in programming a system between the noncancer and cancer states. This paper introduces a platform that can elucidate miRNA and mRNA behavior on a systems level and provides a comprehensive systematic view of both the energetics of the expression levels of RNAs and of their changes during tumorigenicity.

Citing Articles

Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy.

Vaxevanis C, Bachmann M, Seliger B J Immunother Cancer. 2024; 12(8).

PMID: 39209767 PMC: 11367391. DOI: 10.1136/jitc-2024-009774.


MicroRNA-34 and gastrointestinal cancers: a player with big functions.

Gao W, Zhou J, Morshedi M Cancer Cell Int. 2024; 24(1):163.

PMID: 38725047 PMC: 11084024. DOI: 10.1186/s12935-024-03338-w.


The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer.

Sharon S, Daher-Ghanem N, Zaid D, Gough M, Kravchenko-Balasha N Front Oral Health. 2023; 4:1180869.

PMID: 37496754 PMC: 10366623. DOI: 10.3389/froh.2023.1180869.


Identification and validation of the microRNAs and hub genes for pancreatic ductal adenocarcinoma by an integrated bioinformatic analysis.

Xin W, Fu Y, Chen L, Ding H, Feng T, Sun J J Gastrointest Oncol. 2023; 14(2):719-732.

PMID: 37201049 PMC: 10186514. DOI: 10.21037/jgo-23-192.


Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review.

Zhang Y, Guo P, Ma Z, Lu P, Kebebe D, Liu Z J Nanobiotechnology. 2021; 19(1):255.

PMID: 34425832 PMC: 8381574. DOI: 10.1186/s12951-021-01002-3.


References
1.
Yang Z, Dong D, Zhang Z, Crabbe M, Wang L, Zhong Y . Preferential regulation of stably expressed genes in the human genome suggests a widespread expression buffering role of microRNAs. BMC Genomics. 2013; 13 Suppl 7:S14. PMC: 3521228. DOI: 10.1186/1471-2164-13-S7-S14. View

2.
Leber M, Efferth T . Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 2009; 34(4):881-95. DOI: 10.3892/ijo_00000214. View

3.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

4.
Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z . GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009; 10:48. PMC: 2644678. DOI: 10.1186/1471-2105-10-48. View

5.
Wang X, Ling C, Bai Y, Zhao J . MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat Rec (Hoboken). 2010; 294(1):88-92. DOI: 10.1002/ar.21287. View